Clinical Trial Update: Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating recombinant protein Ecallantide to reduce blood loss during coronary bypass grafting or valve surgery; study terminated with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Bypass Grafting
• Valve Disease

Drugs mentioned

• Ecallantide (ecallantide)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Blood Loss, Surgical | Phase 2 | Status: TERMINATED | Results posted: 2015-07-08